Mustang Bio gets 180-day Nasdaq compliance extension

Q: When is MBIO's extended Nasdaq bid-price compliance deadline?

Mustang Bio has until April 12, 2027, under an additional 180-calendar-day grace period granted by Nasdaq staff. To regain compliance, it must evidence a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days, generally not more than 20 consecutive business days.

Q: Will MBIO be delisted if it misses its Nasdaq deadline?

If Mustang Bio does not regain compliance by April 12, 2027, Nasdaq staff will provide written notification that its common stock will be delisted. The company may appeal the staff’s determination to the Nasdaq Hearings Panel, although an appeal would not pause any suspension of trading.

Nasdaq says compliance can be shown with a closing bid of at least $1.00 for a minimum of 10 consecutive business days.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Mustang Bio, Inc. received an additional 180-calendar-day grace period, through April 12, 2027, to regain Nasdaq’s $1.00 minimum bid-price compliance after it failed to meet the initial deadline of October 12, 2026. Compliance can be demonstrated with a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days, generally not more than 20 consecutive business days.

If Mustang Bio does not regain compliance by April 12, Nasdaq staff will notify the company that its common stock will be delisted. The company may appeal to the Nasdaq Hearings Panel, but an appeal would not pause any trading suspension. Mustang Bio intends to take all reasonable measures available, including a reverse stock split if necessary, and said there can be no assurance it will regain compliance.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance works How Sentiment works

1 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

None.

Negative

Major point. Forward-looking: it has not happened yet and may not happen.Failure to regain compliance by April 12, 2027 triggers Nasdaq staff's delisting notice.

Filing Explained

The company describes a reverse split as a possible, not completed, compliance measure; if used, it would reduce the share count and raise the per-share price proportionally, without changing company value by itself.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Key Figures

Additional grace period: 180 calendar days Extended compliance deadline: April 12, 2027 Minimum closing bid price: $1.00 per share +3 more

6 metrics

Additional grace period 180 calendar days Nasdaq granted the additional period to regain bid-price compliance.

Extended compliance deadline April 12, 2027 End of the second grace period.

Minimum closing bid price $1.00 per share Bid-price threshold for continued Nasdaq listing.

Minimum qualifying period 10 consecutive business days Minimum period at or above the required closing bid price.

Generally applicable maximum period 20 consecutive business days The filing says the qualifying period is generally not more than this duration.

Initial grace-period deadline October 12, 2026 Mustang Bio had not regained compliance by this date.

Key Terms

Bid Price Requirement, continued listing requirement, reverse stock split, Nasdaq Hearings Panel

4 terms

Bid Price Requirement regulatory

"regain compliance with the Bid Price Requirement"

A bid price requirement is a rule that specifies the minimum price a buyer must offer per share when making an official purchase proposal, tender offer, auction bid, or similar transaction. It matters to investors because it sets a floor for negotiations and valuation—like a reserve price in an auction—ensuring bids meet regulatory, contract or market standards and helping shareholders and markets judge whether an offer is fair or likely to succeed.

continued listing requirement regulatory

"minimum bid price requirement for continued listing"

Rules a stock exchange sets that a publicly traded company must follow to keep its shares listed, such as minimum share price, market value, shareholder equity, and timely financial reporting. These rules matter to investors because failing them can lead to removal from the exchange, which can make shares harder to buy or sell and often lowers their value — like a club with membership requirements where losing eligibility restricts access and signals trouble.

reverse stock split financial

"effecting a reverse stock split, if necessary"

A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.

Nasdaq Hearings Panel regulatory

"appeal the Staff’s determination to the Nasdaq Hearings Panel"

A Nasdaq hearings panel is a group of experts that reviews cases when a company's stock listing is at risk of being removed from the exchange. They evaluate whether the company has met certain standards and determine if it can keep trading on Nasdaq. This process matters to investors because it can affect a company's ability to raise money and maintain credibility in the market.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is MBIO's extended Nasdaq bid-price compliance deadline?

Mustang Bio has until April 12, 2027, under an additional 180-calendar-day grace period granted by Nasdaq staff. To regain compliance, it must evidence a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days, generally not more than 20 consecutive business days.

Will MBIO be delisted if it misses its Nasdaq deadline?

If Mustang Bio does not regain compliance by April 12, 2027, Nasdaq staff will provide written notification that its common stock will be delisted. The company may appeal the staff’s determination to the Nasdaq Hearings Panel, although an appeal would not pause any suspension of trading.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/15/2026 - 04:06 PM EDT Accepted by SEC EDGAR 10/15/2026 - 04:05 PM EDT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): October 13, 2026

Mustang Bio, Inc.

(Exact Name of Registrant as Specified in Charter)


Delaware	001-38191	47-3828760
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

95 Sawyer Road, Suite 110

Waltham, Massachusetts 02453

(Address of Principal Executive Offices)

(781) 652-4500

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	MBIO	Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events

As previously disclosed, on April 15, 2026, Mustang Bio, Inc. (the “Company”) received a notice from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the bid price of the Company’s common stock, par value $0.0001 per share (“Common Stock”), had closed below $1.00 per share for 30 consecutive business days and, as a result, the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2), which sets forth the minimum bid price requirement for continued listing on the Nasdaq Capital Market (the “Bid Price Requirement”). The Staff notice had no immediate effect on the listing of the Company’s Common Stock on Nasdaq.

In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was afforded an initial 180-calendar day grace period, or until October 12, 2026, to regain compliance with the Bid Price Requirement. The Company was unable to demonstrate compliance with the Bid Price Requirement by that date. However, the Company submitted a request for an additional 180-calendar day grace period based upon (i) the Company’s belief that, as of October 12, 2026, it satisfied the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on The Nasdaq Capital Market, except for the Bid Price Requirement, and (ii) the Company’s written notice to Nasdaq of its intention to cure the deficiency during the second grace period by effecting a reverse stock split, if necessary.

On October 13, 2026, the Company received a letter from the Staff granting the Company’s request for an additional 180-calendar day period, or until April 12, 2027, to regain compliance with the Bid Price Requirement. Compliance can be achieved by evidencing a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days (but generally not more than 20 consecutive business days) during the second 180-calendar day grace period. In the event the Company does not regain compliance by the end of the second grace period, the Staff will provide written notification that the Company’s Common Stock will be delisted. At that time, the Company may appeal the Staff’s determination to the Nasdaq Hearings Panel, although an appeal would not pause any suspension of trading.

The Company intends to closely monitor the closing bid price of its Common Stock and to take all reasonable measures available to regain compliance under the Nasdaq Listing Rules and remain listed on Nasdaq, including effecting a reverse stock split, if necessary. However, there can be no assurance that the Company will ultimately regain compliance with all applicable requirements for continued listing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	Mustang Bio, Inc.
Date: October 15, 2026
	By:	/s/ Manuel Litchman, M.D.
		Manuel Litchman, M.D.
		President, Chief Executive Officer and Interim Chief Financial Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents